Eva K. Havrdová: Nové trendy v léčbě RS | RS kompas
Eva HAVRDOVA | Charles University in Prague, Prague | CUNI | Department of Neurology (2. LF) | Research profile
Environmental Factors Associated with Disease Progression after the First Demyelinating Event: Results from the Multi-Center SET Study | PLOS ONE
Multiple sclerosis today: Disease monitoring, biomarkers and family planning - touchNEUROLOGY
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
Eva HAVRDOVA | Charles University in Prague, Prague | CUNI | Department of Neurology (2. LF) | Research profile
Eva HAVRDOVA | Charles University in Prague, Prague | CUNI | Department of Neurology (2. LF) | Research profile
Multiple sclerosis today: Disease monitoring, biomarkers and family planning - touchNEUROLOGY
PDF) Myxovirus Resistance Protein A mRNA Expression Kinetics in Multiple Sclerosis Patients Treated with IFNβ | Eva Havrdova - Academia.edu
Effects of High and Low Efficacy Therapy in Secondary Progressive Multiple Sclerosis
Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study – ScienceOpen
PDF) Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies
New insights into the burden and costs of multiple sclerosis in Europe: Results of the Czech Republic - Eva Havrdova, Gisela Kobelt, Jenny Berg, Daniela Capsa, Mia Gannedahl, Tomáš Doležal, , The
Eva Kubala Havrdová - Proč nepodléhat strachu | RS kompas
Efficacy and Safety of Ozanimod in the Blinded Extension (120 weeks) of RADIANCE Part A, a Phase 2 Trial in Relapsing Multiple S
Multiple Sclerosis dataBase Independent predictors of time to relapse after CIS in high-risk patients Tim Spelman 1*, Claire Meyniel 1,2*, Maria Trojano. - ppt download
Roztroušená skleróza: Helena jí trpí 20 let, přesto žije spokojený život | Blesk.cz
PDF) Myxovirus Resistance Protein A mRNA Expression Kinetics in Multiple Sclerosis Patients Treated with IFNβ | Eva Havrdova - Academia.edu
Eva Kubala Havrdová - Proč nepodléhat strachu | RS kompas
Management of multiple sclerosis patients in central European countries: current needs and potential solutions
Polska Platforma Medyczna Polish Platform of Medical Research https://ppm.edu.pl Repozytorium Śląskiego Uniwersytetu Medyczneg
Disease-modifying therapies in multiple sclerosis: Current perspectives on the latest data - touchNEUROLOGY
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis | NEJM
Disease-activity-free status in patients with relapsing–remitting multiple sclerosis treated with daclizumab high-yield proces
Nové informace ke Covid 19 a RS - prof. Havrdová | RS kompas
Eva HAVRDOVA | Charles University in Prague, Prague | CUNI | Department of Neurology (2. LF) | Research profile
